PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
CHA Biotech posted revenue growth and a swing to net profit in H1 2026, even as its operating loss widened on expanded digital healthcare and regenerative medicine investment.
Owners' net income turned positive for two straight quarters — KRW 15.6bn in Q1 2026 and KRW 29.3bn in Q2 2026.
Operating losses widened over the same period, so top-line growth did not translate into operating profitability.
Consolidation of Kakao Healthcare and Cha AI Healthcare, along with overseas hospital operations in the US, Australia, Singapore and Japan, drove revenue growth.
US subsidiary Matica Bio is cited as a potential beneficiary of Biosecure Act-driven CDMO demand shifts, but no large-scale order has been disclosed yet.
The debt ratio has stayed in a 150–215% range across the last four fiscal years, warranting continued balance-sheet monitoring.
CHA Biotech, rooted in the CHA Hospital Group, operates a diversified healthcare and bio business spanning advanced regenerative medicine (cell and gene therapy), CDMO, digital healthcare, global hospital operations, and cord blood banking.
In Korea, the company runs GMP facilities linked to its hospital network, including Bundang CHA Hospital, while its US subsidiary Matica Biotechnology operates a customized cell and gene therapy (CGT) CDMO facility in Texas.
The company holds what it describes as one of the world's largest cell libraries, spanning embryonic and adult stem cells to immune cells, supported by isolation, culture and cryopreservation technologies, and has built a five-site global CGT CDMO network comprising Matica Bio, Matica Bio Labs, the CGB facility in Pangyo, Bundang CHA Hospital GMP, and Matica Bio Japan.
In H1 2026, the digital healthcare segment expanded as Kakao Healthcare and Cha AI Healthcare were newly consolidated into group results. Overseas, the global healthcare business operating hospitals and healthcare services in the US, Australia, Singapore and Japan showed steady growth.
Affiliates include CMG Pharm (improved new drugs and orally dissolving films), Cha Cares, and iCord (cord blood banking), whose business expansion also contributed to revenue growth.
In immune cell therapy, the company is expanding clinical research on autologous NK cell therapies targeting solid tumors such as liver cancer, glioblastoma and biliary tract cancer using its proprietary NK cell culture technology, while also pursuing next-generation CAR-NK therapy development.
Because the CDMO, digital healthcare and global hospital businesses sit at different stages of maturity, group-level results reflect a mix of profit and loss across segments.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩298.9B | -₩20.8B | −6.9% |
| 2025Q3 | ₩318.7B | -₩8.1B | −2.5% |
| 2025Q4 | ₩346.5B | -₩7.4B | −2.1% |
| 2026Q1 | ₩329.7B | -₩30.7B | −9.3% |
| 2026Q2 | ₩316.4B | -₩28.2B | −8.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩844.6B | -₩47.1B | -₩47.5B | −5.6% | −16.3% | 146.5% |
| 2023 | ₩954B | -₩9.6B | -₩8.4B | −1.0% | −3.0% | 162.9% |
| 2024 | ₩1T | -₩59.7B | -₩8.1B | −5.7% | −2.8% | 205.3% |
| 2025 | ₩1.3T | -₩48.8B | -₩109.9B | −3.8% | −36.1% | 214.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
Annual revenue rose for four consecutive years, from KRW 844.6bn in 2022 to KRW 954.0bn in 2023, KRW 1,045.0bn in 2024 and KRW 1,268.3bn in 2025.
Operating losses, however, showed no consistent improvement: they narrowed from -KRW 47.1bn in 2022 to -KRW 9.6bn in 2023, then widened again to -KRW 59.7bn in 2024 and -KRW 48.8bn in 2025.
Owners' net income remained in deficit through 2022 (-KRW 47.5bn), 2023 (-KRW 8.4bn) and 2024 (-KRW 8.1bn) before the loss expanded sharply to -KRW 109.9bn in 2025.
The quarterly pattern tells a different story: owners' net loss narrowed from -KRW 58.5bn in Q2 2025 to -KRW 11.8bn in Q3 2025 and -KRW 18.8bn in Q4 2025, before turning positive for two consecutive quarters — +KRW 15.6bn in Q1 2026 and +KRW 29.3bn in Q2 2026.
Operating losses over the same window actually widened, from -KRW 20.8bn in Q2 2025 to -KRW 30.7bn in Q1 2026 and -KRW 28.2bn in Q2 2026, suggesting the net income improvement stemmed from factors other than core operating recovery.
Indeed, in its H1 2026 results disclosure the company attributed the swing to net profit to portfolio realignment and asset efficiency measures, and on a standalone basis cited the sale of its Solidus Investment stake as a contributor to net income improvement.
Revenue growth was driven mainly by the consolidation of Kakao Healthcare and Cha AI Healthcare along with expansion of overseas healthcare operations in the US, Australia, Singapore and Japan, while the widening operating loss was attributed to expanded AI-based digital healthcare investment and increased R&D spending on advanced regenerative medicine.
The global cell and gene therapy (CGT) industry is seeing rising demand for contract development and manufacturing (CDMO) services, and the US Biosecure Act, if enacted, is expected to restrict Chinese CDMO firms such as WuXi Biologics from the US market.
According to the US biotechnology industry association, roughly 79% of US biotech companies currently rely on Chinese CDMO providers, implying substantial supply-chain realignment if the law takes effect.
While existing contracts would be grandfathered until 2032, new contracts are increasingly likely to favor non-Chinese suppliers, and CDMO companies from Korea, Japan and India are competing to secure US-based production footprints to capture this gap.
CHA Biotech's US subsidiary Matica Bio, which became the first Korean company to complete a customized CGT CDMO facility in Texas in 2022, is positioning itself to benefit from this shift.
However, the CDMO industry is characterized by high entry barriers and strong customer stickiness once contracts are signed, meaning order wins typically take considerable time to convert into revenue.
In digital healthcare, the consolidation of Kakao Healthcare gives the company a foothold in AI-based healthcare platform competition, though this business remains at an early stage relative to larger domestic and global platform operators.
CHA Biotech is building a Cell Gene Biobank (CGB) facility at the second Pangyo Techno Valley to expand cell and gene therapy production capacity, designed to simultaneously produce mRNA, viral vectors and plasmid DNA under one roof as an Asian production hub.
US subsidiary Matica Bio disclosed at the June 2026 BIO International Convention plans to expand a second plant within two to three years, stating it expects Biosecure Act-driven demand to significantly boost revenue.
In immune cell therapy, the company signed an MOU with Miltenyi Biotec Korea in August 2025 to jointly develop an automated mass-production process for allogeneic CAR-NK cells, aiming to secure production technology at scales above 50 liters needed for commercialization.
Affiliate CMG Pharm is pursuing a stock consolidation to address concerns over administrative-issue designation, while simultaneously expanding its pipeline of improved and new drugs, including the orally dissolving film Mezopi ahead of a planned US market entry.
The company was also selected for a consortium under the Ministry of Science and ICT's K-CGTAP platform project for advanced biologics quality assessment, participating in cell line banking and quality assessment technology development.
However, the CGT CDMO segment has yet to disclose any large-scale order either domestically or overseas, making the timing of any conversion from investment to actual orders and revenue a key point to watch going forward.
CHA Biotech's share price reflects an earnings structure that mixes years of operating losses with a recent turn to net profit, making valuation difficult to assess through profit metrics alone.
Its price-to-book ratio has often traded at a premium to net asset value, which can be interpreted as reflecting market expectations for future growth businesses such as cell and gene therapy and digital healthcare.
Conversely, profit-related metrics are not yet indicative of a stable earnings base, given that operating losses have persisted despite the recent net income turnaround.
On the dividend front, the company has a multi-year history of not paying dividends, consistent with a capital allocation policy weighted toward reinvestment rather than shareholder returns.
Ultimately, valuation for this name is likely to hinge heavily on how quickly the CDMO and digital healthcare businesses convert investment into orders and revenue, and on whether the balance sheet structure improves.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
US subsidiary Matica Bio became the first Korean company to complete a customized CGT CDMO facility in Texas in 2022.
If the Biosecure Act takes effect, US biotech companies reliant on Chinese CDMOs may need to realign their supply chains, and the company has announced plans to expand a second plant within two to three years in response.
Combined with the CGB facility in Pangyo, this would complete a CGT CDMO network spanning Korea, the US and Japan.
Revenue has grown for four consecutive years, driven by the consolidation of Kakao Healthcare and Cha AI Healthcare along with expansion of overseas healthcare operations in the US, Australia, Singapore and Japan. This trend continued into H1 2026, forming a diversified base for top-line growth.
Owners' net income turned positive for two consecutive quarters, at KRW 15.6bn in Q1 2026 and KRW 29.3bn in Q2 2026. Portfolio realignment, asset efficiency measures and stake sales have been cited as drivers, reflecting the company's efforts toward balance-sheet stabilization.
While revenue grew for four straight years, operating income remained negative throughout 2022–2025, with losses actually widening in 2024–2025.
Operating losses in Q1 and Q2 2026 also expanded year-on-year to KRW 30.7bn and KRW 28.2bn, respectively, showing that top-line growth has not translated into improved profitability.
Even after completing its facility in 2022, Matica Bio has yet to disclose any large-scale order win, and past reports have noted that losses continued to accumulate despite expanded investment. Whether the Biosecure Act translates from an 'opportunity' into actual 'results' remains unconfirmed.
The debt ratio rose for four consecutive years, from 146.5% in 2022 to 214.8% in 2025. Net income has also swung sharply on a quarterly basis due to one-off factors such as asset sales and portfolio realignment, meaning more time is needed to confirm a stable earnings trajectory.
Investment is being spread simultaneously across multiple growth businesses — regenerative medicine, digital healthcare and CDMO — which disperses resources and makes it difficult to predict when each segment's profitability will improve. The CGT CDMO business in particular has high entry barriers, which can extend the investment payback period.
In the second half of 2025, the company withdrew a planned additional investment of roughly KRW 20bn in Matica Bio amid a correction request from the Financial Supervisory Service and shareholder pushback.
This illustrates that large-scale fundraising and subsidiary investment plans can be altered as they undergo market and regulatory scrutiny.
With operating losses persisting for years, the debt ratio has trended upward, and operating cash flow was negative at -KRW 72.5bn in 2025. If losses persist over the long term, the company may need to repeat financial responses such as additional fundraising or asset sales.
The Q3 2026 quarterly report is due for DART filing — a key point to check whether net income profitability extends to a third straight quarter and whether the widening operating loss trend stabilizes.
Check progress on the completion and start-up of the Pangyo CGB (Cell Gene Biobank) facility — delays versus the original target have been flagged, making the actual completion and operation timeline worth monitoring.
Monitor progress on US Senate deliberation and potential enactment of the Biosecure Act — whether the law takes effect and which companies are named on the restricted list could directly affect Matica Bio's order opportunities.
Watch for disclosure of any large-scale CDMO order win by Matica Bio or Matica Bio Labs — a key indicator of whether Biosecure Act-related expectations convert into actual contracts.
Confirm completion of affiliate CMG Pharm's stock consolidation and whether concerns over administrative-issue designation have been resolved.
CHA Biotech achieved both revenue growth and a swing to owners' net profit in H1 2026, but its widening operating loss shows that the net income improvement relied heavily on one-off factors such as asset efficiency measures and portfolio realignment.
With regenerative medicine CDMO, digital healthcare, and global hospital operations sitting at different stages of maturity, it is difficult to pinpoint a single timeline for group-wide profitability improvement.
The potential shift of CDMO demand driven by the US Biosecure Act is a logically sound opportunity, but it has not yet been confirmed through any large-scale order disclosure. A rising debt ratio and continued negative operating cash flow remain balance-sheet metrics worth watching.
Going forward, Q3 earnings, the CGB facility's operational status, Biosecure Act developments, and any CDMO order disclosures will likely serve as key checkpoints for gauging the company's earnings direction. This report is for informational purposes only and does not constitute a buy or sell recommendation.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.